PHP Biotech Reports Preclinical Efficacy and Safety Data for PHP53-nb, a First-in-Class Nanobody for Mutant-p53 Tumors

On November 11, 2026 PHP Biotech International Inc., a privately held biotechnology company developing humanized nanobody therapeutics for aggressive solid tumors, reported preclinical efficacy, safety and biodistribution results for its lead candidate, PHP53-nb, and outlined the experimental program it expects to complete ahead of regulatory testing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PHP53-nb is a first-in-class humanized camelid nanobody engineered to induce apoptosis in tumor cells carrying mutant p53 — a mutation class that has resisted conventional drug development for decades. At roughly one-tenth the size of a conventional monoclonal antibody, the molecule potentially carries lower immunogenicity, greater stability and more efficient tissue and tumor penetration. It selectively targets a receptor expressed on tumor cells, uPAR, an for internalization, then acts inside the cell through proteasome modulation, ER stress and unfolded protein response activation, mitochondrial permeabilization and caspase cascade activation.

Activity across multiple p53 mutations. In a twelve-line cell panel, PHP53-nb decreased cell viability in tumor lines carrying both DNA-binding-domain and structural TP53 mutations: triple-negative breast cancer (MDA-MB-231, R280K; HCC1395, R175H), pancreatic cancer (MiaPaCa-2, R248W; Su86.86, G245S; BxPC-3, Y220C), non-small cell and small cell lung cancer (NCI-H820, T284P; NCI-H1963, H214R), osteosarcoma (KHOS/NP, R156P) and neuroblastoma (SK-N-BE(2), C135F). All results were statistically different from the non-tumorigenic MCF10A control. A wide safety margin. In zebrafish, no lethality was observed up to 20 times the MDA-MB-231 in vitro IC50, and malformations appeared only at concentrations at or above that threshold (p<0.0001). Published work places doxorubicin’s LD50 at six times plasma concentration in the same model. At non-toxic doses, PHP53-nb produced tumor growth reduction comparable to doxorubicin in zebrafish TNBC xenografts, with activity observed against both primary tumor and metastatic burden.

In vivo results in mice. In a triple-negative breast cancer xenograft model, PHP53-nb dosed at 200 mg/kg achieved 41% tumor growth inhibition by day 29, compared with 59% for paclitaxel at 15 mg/kg (p<0.05, two-sided Welch’s t-test versus vehicle). Fluorescent biodistribution imaging at 20 mg/kg showed efficient systemic distribution, delivery to the target tissue, and persistent tumor localization at least 24 hours after administration — addressing rapid clearance and low target retention, two limitations that have historically constrained nanobody development.

"Mutant p53 sits inside a large share of human cancers, and the field has spent decades trying to reach it," said Robert Gahagen, Chief Executive Officer of PHP Biotech. "What these data show is a molecule that gets inside the cell, works across several different mutations rather than one, and does it with a safety margin that leaves real room to dose. That combination is what makes this a program worth partnering on."

PHP53-nb is built on GEN01-AD, PHP Biotech’s proprietary nanobody platform. The scaffold embeds a theragnostic sequence directly in the nanobody paratope, producing a single recombinant molecule with no linker or conjugation chemistry — a design intended to lower manufacturing cost and improve commercial viability. GEN01-AD can carry other bioactive sequences as well, with potential applications in immunology, antimicrobial therapy, imaging and metabolic disease alongside oncology. Four patents covering the peptide, the scaffold, the production method and the lead molecule have been filed in the United States and under the Patent Cooperation Treaty.

"The scaffold is what makes the rest possible," said Patrícia Bezerra, PhD, Research Leader at PHP Biotech. "It gives bioactive sequences stability and a possible route into the cell, and it manufactures like a single protein rather than a conjugate. The same chassis can generate multispecifics, antibody-drug conjugates and radioligands."

. PHP Biotech’s analysis of GLOBOCAN 2022, IARC TP53 Database v20, COSMIC v98 and TCGA PanCancer Atlas data across eight tumor types puts five-year prevalence at approximately 9.61 million patients, of whom roughly 5.52 million carry a TP53 mutation and about 828,000 carry one of the three hotspot variants represented in the company’s responsive cell panel — R175H, G245S and R280K.

Planned work through the first quarter includes mechanism-of-action validation, toxicity and efficacy studies in mice, ADME and blood-brain-barrier studies, an in vivo combination study with anti-PD-1 therapy, technology transfer to a contract development and manufacturing organization, and regulatory testing. The program is supported by research and manufacturing partners including ATUM, BioReperia, TD2 Precision Oncology, Pace Life Sciences, Thermo Fisher Scientific, PanomeBio and RayBiotech.

PHP Biotech is engaged in partnering discussions with pharmaceutical companies and investors evaluating PHP53-nb as both a standalone candidate and an add-on therapeutic in tumors carrying p53 mutations.

(Press release, PHP Biotech, NOV 11, 2026, View Source [SID1234674626])

Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds

On November 11, 2026 Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, reported that the Company has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have agreed to exercise in full for cash their Existing Warrants to purchase up to an aggregate of 2,777,778 shares of common stock of the Company ("common stock") at a reduced exercise price of $1.08 per share. In consideration for such cash exercises, the Company will issue new unregistered common stock purchase warrants (the "Inducement Warrants") to purchase up to an aggregate of 13,888,890 shares of common stock at an exercise price of $1.08 per share. The Inducement Warrants will be exercisable on or after the date on which the Company obtains the required stockholder approval and will expire five years after their initial exercise date. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-298483).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The aggregate gross proceeds from the transaction described herein are expected to total approximately $3.0 million, before deducting placement agent fees and expenses.

Roth Capital Partners is acting as the Company’s financial advisor in connection with this transaction.

The transaction is expected to close on or about November 12, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the transaction for working capital purposes.

The Inducement Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933 (the "Securities Act"). The Inducement Warrants, along with the common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of common stock issuable upon exercise of the New Warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or exemption under the securities laws of any such state or jurisdiction.

(Press release, Aptevo Therapeutics, NOV 11, 2026, View Source [SID1234674611])

FDA Meeting Could Put NeOnc’s NEO100 Experimental Brain Cancer Drug on Faster Track

On November 11, 2026 NeOnc Technologies Holdings (NASDAQ: NTHI) reported a Type B End-of-Phase meeting, scheduled for early January 2027, with the U.S. Food and Drug Administration (FDA), to discuss a potential accelerated approval pathway for its experimental intranasal brain cancer treatment NEO100, putting the company’s regulatory strategy in focus as it prepares for a randomized Phase 3 study.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NeOnc intends to seek FDA feedback on whether its existing clinical and nonclinical evidence could support a 505(b)(2) New Drug Application (NDA) seeking accelerated approval for recurrent or progressive IDH-mutant grade 4 astrocytoma.

The company also plans to discuss NEO100-012, a proposed multicenter, randomized, controlled Phase 3 trial comparing NEO100 against investigator’s-choice standard-of-care chemotherapy. Overall survival would serve as the primary endpoint.

Phase 2a results provide the foundation for the FDA discussion

The company’s accelerated approval ambitions follow results announced August 12, 2026, from the Phase 2a portion of its NEO100-01 study.

According to NeOnc, the study achieved a six-month progression-free survival (PFS-6) rate of 48.9%, with a 95% confidence interval of 26.3% to 68.1%. This exceeded the protocol-defined 20% historical benchmark for standard-of-care treatment, with a reported one-sided p-value of 0.0047.

The efficacy analysis included 24 patients with IDH1-mutant tumors, 21 of whom had grade 4 disease. Five patients remained on treatment at the interim database lock on June 24, 2026.

NeOnc also reported that independent central MRI assessments were used and that no treatment-related Grade 3 or higher adverse events, treatment-related serious adverse events, or discontinuations due to treatment-related adverse events had occurred.

These results offer an encouraging signal, particularly given the limited treatment options available to patients with recurrent high-grade astrocytoma.

Why the accelerated approval strategy matters

The FDA’s Accelerated Approval Program allows certain treatments for serious conditions to receive earlier approval based on a surrogate endpoint or intermediate clinical endpoint reasonably likely to predict clinical benefit.

For cancer treatments, progression-free survival can potentially serve as an endpoint supporting regulatory consideration, depending on the disease, treatment effect and strength of the supporting evidence.

NeOnc’s NEO100-012 may be underway, with enrollment ongoing, when any potential NDA is submitted. The trial’s final overall survival analysis would then be intended to confirm clinical benefit and support conversion to traditional approval.

A separate question concerns the company’s proposed scientific bridge between published perillyl alcohol data and its proprietary intranasal NEO100 formulation.

The FDA is also expected to discuss the adequacy of the existing nonclinical safety package and whether NEO100 could qualify for Breakthrough Therapy designation.

Insider purchases add another dimension

There is also a notable corporate insider development worth considering.

In its November 5, 2026, third-quarter business update, NeOnc reported that Executive Chairman and CEO Amir Heshmatpour and Dr. Thomas C. Chen purchased a combined 160,016 shares of company common stock for approximately $629,000 in open-market transactions following the Phase 2a results. The company said the purchases were made using personal funds.

Heshmatpour has continued buying shares in the open market, purchasing 80,000 shares for approximately $269,082 across November 5, 6 and 9, according to SEC Form 4 filings. The transactions included 30,000 shares at a weighted average price of $3.167 on November 5, another 40,000 at $3.3875 on November 6, and 10,000 shares at $3.86 on November 9. The purchases were made with personal funds, and no new shares were issued by the company in connection with the transactions.

The latest purchases bring Heshmatpour’s reported 2026 open-market buying to 271,000 shares, representing approximately $1.11 million, according to NeOnc, and are worth mentioning because they occurred after the August clinical announcement and before the latest regulatory development.

Short interest points a squeeze setup

Insider buying can provide an additional indication of management confidence, particularly when executives purchase shares in the open market rather than receiving equity compensation.

Market data for October 30, 2026, showed approximately 920,631 shares sold short, representing approximately 7.03 days to cover, well above the coveted 5 days to cover threshold, and several sites are reporting even larger amounts, which could be an even more powerful force.

November and January bring important catalysts

The FDA meeting is not the company’s only upcoming milestone.

NeOnc announced in its November 5 third-quarter update that it expects to present updated NEO100 Phase 1/2a results and NEO212 Phase 1 data at the Society for Neuro-Oncology’s annual meeting on November 13, 2026.

The NEO100 presentation will include updated results from the clinical study and compassionate-use experience.

Additional information from these presentations could help investors assess whether the August topline findings remain consistent with the updated clinical dataset.

The company also has a separate regulatory milestone involving NEO212, its oral investigational drug candidate. An FDA End-of-Phase 1 Type B meeting concerning NEO212 is scheduled for November 17, 2026, according to the company’s September announcement.

For NEO100, the early January 2027 meeting will be the next major regulatory event, with the company saying it expects to provide an update after receiving and reviewing the FDA’s official meeting minutes, as the content of those minutes could be more important than the announcement that the meeting itself has been scheduled.

(Press release, Neonc, NOV 11, 2026, View Source [SID1234674627])

enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC

On November 11, 2026 enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, reported updated results from the pivotal Cohort 1 of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene). Data from Cohort 1, which enrolled 125 patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without concomitant papillary disease, are expected to form the basis for a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"For patients with high-risk BCG-unresponsive NMIBC, we need therapies that provide meaningful and durable disease control while minimizing treatment-related toxicity and burden," said Ashish M. Kamat, MD, Professor of Urologic Oncology at The University of Texas MD Anderson Cancer Center and Primary Investigator of the LEGEND trial. "The updated LEGEND data are encouraging, demonstrating clinically meaningful antitumor activity with a favorable tolerability profile. Combined with its straightforward administration and handling requirements, detalimogene has the potential to become a valuable addition to our bladder-preserving treatment options, particularly in community urology practices where ease of administration and practical considerations can influence treatment selection."

"The updated results from Cohort 1 demonstrate encouraging improvements across all key efficacy measures as the data have matured, bringing detalimogene’s efficacy profile to date within range of approved products for this indication," said Ron Cooper, President and Chief Executive Officer, enGene. "Importantly, our recent interactions with the FDA provide a clear path to initiate a BLA submission before year-end 2026, representing a significant step toward bringing detalimogene to patients, with potential approval in 2027."

Mr. Cooper continued, "In parallel, we are preparing for commercialization, with a focus on positioning detalimogene for broad adoption across community urology practices, where more than 75% of high-risk, BCG-unresponsive NMIBC patients receive care. We believe detalimogene’s differentiated ease of use and handling could facilitate integration into existing treatment settings, helping expand access to a new bladder-preserving treatment option for patients."

LEGEND Pivotal Cohort Update

The following efficacy data are based on 120 efficacy-evaluable patients enrolled in Cohort 1 as of the data cutoff date, October 29, 2026.

Efficacy Overview:

CR at any time of 56% (CI:47%, 65%) (n=120)
Landmark 12-month CR rate is 24% (CI: 16%, 33%) (n=110)
1 patient is pending the 12-month landmark disease assessment
Median follow-up for responders increased to 12.0 months from 9.2 months since April 2026 data analysis
Preliminary Kaplan-Meier Estimate of DoR ≥12 months is 43% (CI: 30%, 55%)
9 patients are pending the DoR ≥12 months disease assessment
8 patients currently in maintenance are pending a durability assessment
1 patient is pending the 12-month landmark disease assessment
100% of patients who entered maintenance and had been assessed for durability have recorded durable responses
Median duration of complete response is 10.1 months (CI: 7.5, Not Estimable)
97% of all efficacy evaluable patients were free from progression to muscle-invasive or metastatic bladder cancer, defined as T2 or greater disease
100% of responders were free from progression to T2 or greater disease in the bladder
86% of all efficacy evaluable patients remain free from cystectomy
96% of responders remain free from cystectomy
Safety Overview:

The overall tolerability profile associated with detalimogene has been favorable. Of the 125 patients assessed for safety in Cohort 1, 59% experienced at least one TRAE, which were mainly Grade 1/2 in severity. The most common TRAEs were fatigue (21%), dysuria (16%), pollakiuria (16%), and bladder spasm (13%), micturition urgency (13%), and urinary tract infection (10%). Only 4% of patients experienced Grade 3 TRAE, with just 2% of patients experiencing a serious TRAE. No Grade 4 or Grade 5 TRAEs were reported. TRAEs leading to dose discontinuation (1%) or dose interruption (4%) were rare.

Regulatory Update and Anticipated Milestones:

Following the Company’s pre-BLA meeting with the FDA, enGene reached alignment on key components of the planned BLA for detalimogene, including the efficacy evaluable patient population. The Company expects to initiate the submission by year-end 2026 and plans to complete the BLA submission in the first half of 2027, with potential FDA approval in 2027. In addition, the Company expects to provide an update on the detalimogene plus surfactant bladder rinse cohort mid- 2027.

Conference Call and Webcast

enGene will host a conference call and webcast on November 11, 2026, at 4:30 p.m. Eastern Time to discuss the updated LEGEND data and provide an overview of the regulatory path for detalimogene. Details for the conference call and webcast are included below.

Conference Call Dial-in Numbers:

North America Toll-Free: +1 833-461-5787
International Toll: +1 585-542-9983
Additional International Dial-Ins can be found here

Meeting ID: 485 327 198

Webcast Link: View Source

A link to the webcast will also be available on the Investors section of enGene’s website. A replay of the webcast will be available at this same link within two hours of the event’s conclusion.

About Non-Muscle Invasive Bladder Cancer (NMIBC)

Non-muscle invasive bladder cancer (NMIBC) is a disease that poses a significant burden on both patients and clinics and has a massive economic impact on the healthcare system. NMIBC occurs when cancer cells grow in the tissues that line the interior of the bladder, but the cancer has not yet penetrated the muscle of the bladder wall. NMIBC can present as papillary outgrowths from the bladder wall, which are typically resected, or as carcinoma in situ (CIS), which consists of flat, multifocal lesions that cannot generally be resected. The two forms can also co-occur. About 75%-80% of new bladder cancer diagnoses are NMIBC. Patients suffering from high-risk NMIBC who are unresponsive to the standard of care, Bacillus Calmette-Guérin (BCG), face high rates of disease recurrence (50%-70%) and are potentially subject to full removal of the bladder (cystectomy) as a curative but life-altering next step.

About Detalimogene Voraplasmid

Detalimogene is a novel, investigational, non-viral gene therapy for patients with high-risk, non-muscle invasive bladder cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-unresponsive disease. It is designed to be instilled in the bladder and elicit a powerful yet localized anti-tumor immune response.

Detalimogene was developed using the Company’s Dually Derivatized Oligochitosan (DDX) platform, a technology designed to transform how gene therapies are accessed by patients and utilized by clinicians. Medicines developed with the DDX platform can potentially overcome the limitations of viral-based gene therapies, reduce complexities related to safe handling and cold storage, and streamline both manufacturing processes and administration paradigms.

Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations

Detalimogene has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration (FDA) based on its potential to address the high unmet medical need for patients with BCG-unresponsive carcinoma in situ (CIS) NMIBC with or without resected papillary tumors who are unable or refuse to undergo cystectomy. These designations are intended to expedite the development and review of drugs intended to treat serious or life-threatening conditions and fill an unmet medical need. Detalimogene has also been selected for the FDA’s Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program, designed to facilitate CMC development for therapies with compressed clinical development timeframes based on the anticipated clinical benefits of earlier patient access to the therapy.

About the LEGEND Trial

Detalimogene is being evaluated in the ongoing, open-label, multi-cohort, Phase 2 LEGEND trial to establish its safety and efficacy in high-risk NMIBC. LEGEND’s pivotal cohort (Cohort 1) consists of 125 patients with high-risk, BCG-unresponsive NMIBC with CIS (with or without papillary disease) and is designed to serve as the basis of the Company’s planned Biologics License Application (BLA) filing. In addition to this pivotal cohort, LEGEND includes four additional cohorts, including NMIBC patients with CIS who are naïve to treatment with BCG (Cohort 2a); NMIBC patients with CIS who have been exposed to BCG but have not received adequate BCG treatment (Cohort 2b); BCG-unresponsive high-risk NMIBC patients with papillary-only disease (Cohort 3); and BCG-unresponsive high-risk NMIBC patients with CIS who receive polidocanol plus detalimogene.

(Press release, enGene Therapeutics, NOV 11, 2026, View Source [SID1234674612])

MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies

On November 11, 2026 MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering unmodified, off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies, reported financial results for the third quarter ended September 30, 2026, and highlighted a quarter in which agenT-797 realized pre-commercial revenue, its randomized trial in acute respiratory distress syndrome (ARDS) is advancing , and an ARPA-H program selected the Company’s cells to generate living medicines can be delivered without a freezer. Full financial results will be reported on Thursday, November 12, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

iNKT cells coordinate the immune response a tissue requires: resolving infection and inflammation in severe lung injury, overcoming treatment resistance in cancer and clearing the senescent cells that sustain progression and fibrotic scarring. agenT-797 delivers from inventory – without apheresis, HLA matching or lymphodepletion. MiNK is concentrating its own investment on the randomized ARDS trial and using non-dilutive partners to advance key platform programs.

"We now have a randomized trial running in critical illness, multiple clinical programs enrolling and a path toward pivotal development. This quarter, physicians outside our trials began requesting agenT-797 for their patients, bringing our first pre-commercial revenue," said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics. "The same unmodified iNKT cells, from the same donor, that drove a 77% disease control rate in PD-1-refractory gastroesophageal cancer are now in a placebo-controlled trial in ARDS, where nearly four in ten patients die and no effective approved drug changes that outcome. Our focus now is delivering the randomized readout designed to show what these cells can do for these patients."

Third Quarter 2026 and Recent Highlights

Named-Patient Access Reaches Patients in Multiple Countries, Generating First Pre-commercial Revenue

In the third quarter, MiNK recognized its first pre-commercial product revenue from agenT-797 supplied on a paid, per-patient basis under its international named-patient access program, in collaboration with Orphan Drug Consulting and BAP. The program is now open in multiple countries outside the United States. Every request originates with a treating physician for an individually identified patient with serious unmet medical need and is authorized case by case by the applicable health authority; agenT-797 remains investigational.

The program shows that MiNK’s inventory can supply trials and physician-directed access at the same time; that MiNK can move a living cell therapy across borders with full regulatory and safety oversight; and that physicians are requesting it. MiNK intends to expand this access in all markets where regulations allow.

Randomized ARDS Trial Advancing

MiNK’s randomized, placebo-controlled Phase 2 study of agenT-797 plus standard of care in adults with acute lung injury and moderate-to-severe hypoxemic respiratory failure (C-1300-02) continued enrolling in Lviv, Ukraine during the quarter. U.S. dosing is expected before year-end, with data expected 2H2027.

MiNK plans to advance C-1300-02 as an adaptive trial. The initial randomized stage would enroll 124 patients for initial readout in 2H2027 for the potential to expand. MiNK is pursuing a hierarchical design which will evaluate prevention of patients advancing to veno-venous ECMO and all-cause mortality through Day 28. MiNK is seeking FDA feedback on the development plans for the program.

In August, MiNK presented initial Day 28 observations from the first agenT-797-treated patients at the Military Health System Research Symposium. These very sick patients, several with multidrug-resistant infections, demonstrated resolution of fever, improved oxygenation, resolution of ARDS and recovery from ventilator and vasopressor support, with immune markers in blood and lung fluid tracking recovery. No serious adverse events were attributed to agenT-797.

MiNK estimates that approximately 93,000 U.S. patients annually fall within its initial target population of ventilated, pneumonia-associated moderate-to-severe ARDS. Nearly four in ten patients die within 28 days, and no effective FDA-approved drug has been shown to reduce that mortality.

"I treat ARDS in the ICU, and it is the condition I see most often and can do the least about. We keep patients alive and wait for the immune system to right itself, and too often it does not," said Terese Hammond, M.D., Head of Inflammatory and Pulmonary Diseases at MiNK Therapeutics. "Because agenT-797 comes from inventory, with no matching or conditioning, it can be given in the window when it matters, in any ICU that can thaw and infuse it. That is why we are running the randomized trial."

ARPA-H Selects agenT-797 to Prove Cell Therapy Can Be Deployed Without a Freezer

In September, MiNK’s agenT-797 was selected as the therapeutic cell system for the Draper-led Reversible Ambient Biostabilization team under ARPA-H’s BioStabilization Systems (BoSS) program. Supported by up to $87 million in program-wide funding over four years for performers; the initiative seeks to move living medicines from cryogenic storage toward room temperature.

Cold chain is the single largest barrier to taking an allogeneic cell therapy beyond specialized centers. MiNK has already delivered cryopreserved agenT-797 to ventilated patients within days of authorization in a conflict zone; removing the freezer would allow a living immune therapy to be stocked like a conventional drug in community hospitals and austere settings. MiNK participates on a fixed-fee basis, complementing its internally funded clinical priorities.

SITC 2026: One Biology from Oncology to Fibrotic Lung Disease

At SITC (Free SITC Whitepaper) 2026, MiNK presented new preclinical findings demonstrating the potential of unmodified and engineered iNKT therapies to address two mechanisms that defeat current treatments: tumor resistance and cellular senescence.

In a human organoid model of microsatellite-stable (MSS) colorectal cancer with liver metastases – a setting with no approved immunotherapy – botensilimab and balstilimab alone produced no significant tumor-cell killing. Adding agenT-797 shifted suppressive macrophages toward an antigen-presenting phenotype and unlocked killing, providing mechanistic support for the ongoing investigator-sponsored Phase 2 study at Scripps (NCT07550088).

With Imperial College London, MiNK showed that agenT-797 and MiNK-215, the Company’s FAP-targeted, IL-15-armored CAR-iNKT candidate, act as living senolytics, clearing the therapy-induced senescent cells that chemotherapy and radiation leave behind. MiNK-215 also eliminated FAP-expressing fibroblasts that shield tumors and drive scarring. These same cells fuel treatment resistance in cancer and progression in fibrotic lung disease – including in ARDS survivors whose lungs continue to scar after leaving the ICU – giving MiNK a single thread from oncology to the lung. The Company intends to earn it in sequence: randomized evidence first, then senescence and fibrosis in the clinic.

Externally Funded Clinical Programs Advance Alongside the Randomized Trial

An investigator-sponsored Phase 2 study at Scripps is evaluating agenT-797 with botensilimab and balstilimab in patients with MSS colorectal cancer and liver metastases, building on clinical observations in refractory gastrointestinal cancers, including the disease control rate in PD-1-refractory gastroesophageal cancer reported by Memorial Sloan Kettering investigators at AACR (Free AACR Whitepaper) 2026.

At the University of Wisconsin–Madison, an investigator-sponsored Phase 1 study of agenT-797 for graft-versus-host disease (GvHD) prevention, funded by an NIAID STTR award and the Mary Gooze Clinical Trial Award, is moving toward first dosing; the University has informed MiNK that it expects the first patient to be scheduled by December 2026.

Together with the C-Further program in pediatric patients with blood cancers and the ARPA-H BoSS participation, MiNK now has four sources of non-dilutive support advancing its pipeline, allowing the Company to concentrate its own resources on the randomized ARDS readout.

Priorities and Anticipated Milestones into 2027

Activate U.S. ICU sites and begin U.S. dosing in C-1300-02 before year-end 2026; sustain enrollment
Meet with FDA before year-end on the adaptive Phase 2b/3 design and discuss supportive regulatory designations
Report comparative data from the randomized ARDS trial in second half of 2027
Support first patient dosing in the University of Wisconsin GvHD prevention study
Extend named-patient access to additional markets where regulations allow
Advance the ARPA-H BoSS deployability program
Third Quarter 2026 Financial Results

MiNK ended the quarter with $7.5 million in cash and cash equivalents, compared with $8.8 million at June 30, 2026. The Company recognized $0.2 million in pre-commercial product revenue – its first – from agenT-797 supplied through the named-patient access program. Because the program is new, revenue is expected to vary from quarter to quarter based on physician requests and case-by-case regulatory authorizations.

Net loss was $2.6 million, or $0.50 per share, compared with $2.9 million, or $0.65 per share, in the prior-year quarter – a 23% reduction in net loss per share. Cash used in operations decreased to approximately $1.3 million from $2.1 million in the second quarter, the lowest quarterly operating cash use of 2026. For the nine months ended September 30, 2026, net loss was $8.4 million, or $1.69 per share, compared with $9.9 million, or $2.39 per share, in the prior-year period.

General and administrative expense declined 44% to $1.0 million, primarily reflecting lower professional fees and stock compensation expense. Research and development expense increased to $1.8 million from $1.1 million, reflecting randomized Phase 2 activity and the translational analyses presented at scientific meetings during the quarter – spending directed where the randomized trial requires it.

MiNK is prioritizing investment in its randomized clinical program while holding other operating expenses down. The Company is pursuing partnerships and licensing, non-dilutive funding such as its ARPA-H BoSS participation, and potential equity or debt financing to strengthen its balance sheet, with the priority of funding the randomized study through its readout.

(Press release, MiNK Therapeutics, NOV 11, 2026, View Source [SID1234674628])